By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm MolecularMD announced today it has raised $6 million in a Series B equity financing round.

The financing will go toward accelerating the commercial launch of new platforms and related assay content in areas including next-generation sequencing and rare mutation detection, the Portland, Ore.-based firm said. Funds will also be directed at expanding its sales and marketing operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.